Diphtheria, Tetanus, and Pertussis (DTP) Vaccines Market Size, Share & Industry Analysis, By Technology (Inactivated and Others), By Type (DTaP Vaccine, Tdap Vaccine, DT/Td Vaccine, and Others) By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others), and Regional Forecast, 2025-2032

The global diphtheria, tetanus, and pertussis (DTP) vaccines market size was valued at USD 10.23 billion in 2024. The market is projected to grow from USD 11.69 billion in 2025 to USD 33.38 billion by 2032 at a CAGR of 16.2% during the forecast period.

Diphtheria, tetanus, and pertussis (DTP) vaccines refer to a combination vaccine that protects infants and children against three serious bacterial infections: diphtheria, tetanus, and pertussis (whooping cough). Different types of DTP vaccines exist for adults and infants, such as DTaP, Tdap, and others.

The complications associated with pertussis include pneumonia, vomiting, seizures, shortness of breath, and apnea. Tetanus affects nerves all over the body, causing severe muscle spasms, and diphtheria leads to a throat infection, which can block the airway and cause severe breathing problems. Thus, avoiding these serious side effects associated with the disease is expected to increase the adoption of diphtheria, tetanus, and pertussis (DTP) vaccines, available as a preventive measure.

Furthermore, the global diphtheria, tetanus, and pertussis (DTP) vaccines market is witnessing significant growth due to the rising prevalence of bacterial diseases globally. Growing government awareness programs to increase vaccine coverage and technological advancements in vaccine development are propelling the demand & adoption of diphtheria, tetanus, and pertussis (DTP) vaccines.

• For instance, as per the data published by the World Health Organization, in 2022, more than 62,500 cases of pertussis were registered globally, and nearly 39,000 cases were reported in the Western Pacific Region. Pertussis is highly contagious, mainly occurring in infants and young children. Thus, the contagious nature of this disease increases the demand for infant, children, and pregnant women vaccination to decrease the adverse effects and spread of the disease, driving the market growth.

Moreover, the presence of key players such as GSK plc, Sanofi, and Merck & Co. Inc., with vital regulatory-approved products for diphtheria, tetanus, and pertussis (DTP) vaccines, boosts market growth.

MARKET DYNAMICS

MARKET DRIVERS

Rising Prevalence of Bacterial Diseases Boosts Demand for DTP Vaccines

The increasing prevalence of vaccine-preventable respiratory infections globally is one of the major factors driving the market growth. The rising number of cases associated with whooping cough, which is majorly caused due to Bordetella pertussis globally, has shifted the focus toward vaccination. These diseases pose more risk for infants under one year old as their immune systems are still developing. Thus, to prevent these infections, vaccines act as preventive measures and are thus expected to boost the market growth.

• For example, as per the data published by the Centers for Disease Control and Prevention (CDC) under the Provisional 2024 Reports of Notifiable Diseases, around 35,435 Pertussis cases were registered in 2024. Around 6,539 cases were from the 1-6 years age group. This high number of cases amongst the pediatric population increases the demand for active immunization, thus driving the global diphtheria, tetanus, and pertussis (DTP) vaccines market growth.

MARKET RESTRAINTS

Lack of Awareness Regarding Vaccination Schedule to Restrict Market Growth

Lack of awareness and hesitancy regarding vaccination in lower economic countries is a prominent factor restraining the market growth. The concerns regarding vaccine safety, false religious beliefs, and lack of information about benefits associated with immunization are a few factors leading to missed vaccine dosage and incomplete immunization schedules.

As per the WHO, the most commonly missed vaccines include those against measles, rubella, diphtheria, pertussis, and polio. Additionally, inadequate healthcare infrastructure and low public awareness in low-income regions hinder the vaccine delivery and uptake.

• For instance, in May 2025, the Kyrgyz Republic observed European Immunization Week, and data reported by the Ministry of Health of the Kyrgyz Republic showed that more than 90,000 children did not complete the full diphtheria-pertussis-tetanus (DPT-3) vaccination course between 2020 and 2024. By the end of 2024, 22,060 children remained unvaccinated by the DPT-3 vaccine due to refusals associated with religious beliefs, unawareness, and others.

As a result, these scenarios pose a serious risk of disease outbreaks in underserved regions, highlighting gaps in prevention efforts.

MARKET OPPORTUNITIES

Government Initiatives for DTP Vaccination to Offer Lucrative Growth Opportunities

Despite the availability of diphtheria, tetanus, and pertussis (DTP) vaccines, a significant shift in these infectious conditions is observed globally. Therefore, different government organizations are launching awareness programs to increase vaccination coverage among infants, children, and adults. These programs aim at preventing the outbreak of vaccine-preventable diseases and reducing the financial burden on healthcare authorities.

• In April 2025, in China, with the dramatic resurgence of whooping cough (pertussis), on the 39th National Children's Vaccination Day, a nationwide campaign was launched. This aimed to educate families about the adverse effects of pertussis and the importance of timely vaccination.
• Similarly, in December 2023, GAVI announced the introduction of diphtheria, tetanus and pertussis (DTP)-containing vaccine boosters as a part of the new program. Also, the alliance has shifted toward the hexavalent vaccine. This six-in-one vaccine combines the pentavalent vaccine (diphtheria, tetanus, whole-cell pertussis [DTwP], hepatitis B, and Haemophilus influenzae type b) with inactivated polio vaccine (IPV), intending to protect children against common childhood illnesses.

Such initiatives taken by government organizations boost the adoption of diphtheria, tetanus, and pertussis (DTP) vaccines and propel the market growth.

MARKET CHALLENGES

Limited Cold Chain Infrastructure Leading to Wastage, Challenges Market Growth

The DTP vaccine is temperature-sensitive and must be stored between 2°C to 8°C throughout the supply chain to maintain its potency and safety. This generated a major cold chain logistics challenge, especially in low-resource settings where electricity, refrigeration infrastructure, and transportation are unreliable. Additionally, lack of these settings leads to vaccine wastage, reduced efficacy, and potential health risks.

• For instance, as per the National Vaccine Wastage Assessment report, in India, around 13.5% of DPT vaccine was wasted due to a cold chain point. The wastage included both unopened and opened vial wastage. Such scenarios pose a major challenge to the market growth.

DIPHTHERIA, TETANUS, AND PERTUSSIS (DTP) VACCINES MARKET TRENDS

Rising Advancements in Vaccine Development to Demonstrate Future Growth

Most diphtheria, tetanus, and pertussis (DTP) vaccines used for vaccination in pregnancy have been chemically inactivated. The use of chemical inactivation in the production of tetanus and pertussis vaccines has various disadvantages that have prompted a shift toward recombinant technologies.

Chemical inactivation can denature the protein structure of toxins, thus reducing their immunogenicity and leading to a weaker or shorter-lived immune response. This increases the need for multiple booster doses to maintain protection. These challenges have led to a shift of the company's focus toward recombinant vaccine technologies, as detoxification by genetic engineering maintains the conformational and immunological properties of native Pertussis Toxin (PT).

These techniques enable the development of genetically engineered, non-toxic, yet highly immunogenic antigens, offering improved safety, efficacy, and production consistency.

• For instance, in July 2024, BioNet-Asia announced the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its monovalent Recombinant Pertussis Vaccine (RPV). The vaccine is designed to provide more effective and longer-lasting immune protection against pertussis than traditional acellular pertussis vaccines. The vaccine contains a Pertussis Toxin (PT), which is inactivated by recombinant technologies rather than chemicals.

These vaccine technology advancements are expected to bolster the market’s growth during 2025-2032.

Download Free sample to learn more about this report.

SEGMENTATION ANALYSIS

By Technology

Wide Availability of Inactivated Vaccines Boosted Segment Growth

Based on technology, the global market is segmented into inactivated and others.

The inactivated segment held the highest global diphtheria, tetanus, and pertussis (DTP) vaccines market share in 2024. The presence of a wide range of DTP vaccines in inactivated form is a crucial factor driving the growth of the segment in the market. Additionally, increasing the prevalence of diphtheria, tetanus, and pertussis bacteria cases and growing vaccination coverage boost the segment’s growth.

• For instance, as per WHO, in 2023, 84.0% of infants worldwide were vaccinated with 3 doses of diphtheria-tetanus-pertussis (DTP) vaccine. Such explanatory coverage shows vaccine adoption and thus leads to the segment’s growth.

On the other hand, the others segment is expected to grow with a significant CAGR during the forecast period. The rising advancements in vaccine development technologies and decreasing immunogenicity of chemically inactivated vaccines lead to a shift toward recombinant vaccines. These factors are expected to propel the segment’s growth during 2025-2032.

By Type

Widespread Utilization of DTaP Vaccines Bolstered Segment’s Dominance

Based on type, the market is divided into DTaP vaccine, Tdap vaccine, DT/ Td vaccine, and others.

The DTaP vaccine segment dominated the market in 2024. The segment's growth is driven by its effectiveness in protecting children under age 7 collectively against diphtheria, tetanus, and pertussis. The DTaP vaccine contains full-strength doses of all three vaccines. Additionally, increasing approval for the DTaP type vaccine by the regulatory bodies also propels the segment’s growth in the market.

• For instance, in June 2021, Merck & Co., Inc., in collaboration with Sanofi, announced the commercialization of VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine). It is approved for use as a 3-dose series for children from 6 weeks to 4 years of age.

The Tdap vaccine segment held a substantial portion of the market and is expected to grow moderately during the forecast period. The Tdap vaccine is given to children over 7 years and adults to maintain immunity. This vaccine provides a full-strength tetanus vaccine and smaller doses of diphtheria and whooping cough. Tdap is given as a booster dose every 10 years, thus growing slowly during the forecast period. However, with increasing approval of Tdap vaccines the segment’s growth is boosted.

• For instance, in January 2023, the U.S. FDA approved Adacel (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; Tdap) for pregnant women during the third trimester to protect infants younger than 2 months of age against pertussis.

DT/ Td vaccines are expected to hold a comparatively lower share of the market owing to the discontinuation of DT vaccines mainly in the U.S.

By Age Group

Active Immunization Recommendations for Pediatrics to Boost Segment Growth

Based on age group, the segment is bifurcated into pediatric and adults.

The pediatric segment is expected to dominate the global market and grow with a significant CAGR during the forecast period. The rising incidence of DTP in children and the increased risk of fatalities associated with it has shifted the focus toward the completion of immunization schedules among pediatrics, thus boosting the segment’s growth.

• For instance, in July 2024, Gavi, the Vaccine Alliance, in collaboration with UNICEF and WHO, allocated 200 million additional doses of key life-saving vaccines, including diphtheria, tetanus, and pertussis-containing vaccine (DTP) for children in Gavi countries missed during the pandemic. These activities for pediatrics are expected to increase product adoption and market growth globally.

The adult segment held the market's considerable share. The vaccination is indicated every 10 years as booster or during pregnancy in adults. The availability of booster vaccines by the key players for adults augments the segment’s growth.

• For instance, GSK plc offers BOOSTRIX, an active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older.

By Distribution Channel

Increasing Availability of Affordable Vaccine Through Government Suppliers to Boost Segment’s Growth

Based on distribution channel, the global market is segmented into hospital & retail pharmacies, government suppliers, and others.

The government suppliers held the largest share of the market. This is primarily due to the increasing availability of these vaccines under national immunization programs. The government suppliers help procure and distribute vaccines to the underserved areas, thus propelling the segment’s growth in the market.

The hospital and retail pharmacies segment is expected to experience significant growth during the forecast period. This can be attributed to convenient access to vaccinations and scheduled pediatric doses available at these locations, enhancing vaccine distribution through such channels. Furthermore, several countries are reviewing their immunization strategies by allowing pharmacies to offer childhood vaccines to increase the distribution of vaccines via these channels.

• For example, in July 2024, Pharmac, in collaboration with the National Public Health Service at Health New Zealand, announced that residents could receive vaccinations at nearby pharmacies within their communities. This development tracked the removal of restrictions from the Pharmaceutical Schedule, allowing eligible pharmacies to order and receive reimbursement for administering certain childhood vaccines. Such initiatives are anticipated to drive the growth of this segment.

DIPHTHERIA, TETANUS, AND PERTUSSIS (DTP) MARKET REGIONAL OUTLOOK

The global market can be segmented based on region: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

The North America market size stood at USD 5.86 billion in 2024 and is expected to dominate the global market over the forecast period. The rising incidence of infectious disease cases associated with diphtheria, tetanus, and pertussis and strong healthcare infrastructure are boosting the region’s market growth. Furthermore, the presence of key players in the region with robust products for DTP immunization propels the market growth.

U.S.

The U.S. dominated the North America region, owing to the rising incidence of diseases. The availability of vaccines to propel market growth in the U.S.

• For instance, as per the U.S. Centers for Disease Control and Prevention, the number of reported pertussis cases in 2024 is 11,568, four times more than cases reported in 2023.

These rising cases increase the demand for immunization to decrease healthcare expenditure and boost the market growth in the country.      

Asia Pacific

The Asia Pacific market held the second largest share and is estimated to grow at the highest CAGR from 2025 to 2032. The rising number of cases and the presence of key regional players with affordable product offerings augment the region’s growth and increase awareness programs for market growth.

• For instance, in March 2025, the Department of Health & Welfare, India, collaborated with the Department of Education, Government of Meghalaya, to conduct a Td Vaccination Campaign for school children to ensure that the students aged 10-16 receive booster doses. Such initiatives aimed to bolster the adoption and market growth.

Europe

The European region is expected to hold a substantial market share. The presence of advanced healthcare facilities with adequate vaccination programs is the key aspect driving the demand for the product in the European market.

• For instance, in April 2024, the Bavarian Health and Food Safety Authority in Germany and its Centre for Diphtheria were designated as a WHO collaborating center (WHO CC). This center aimed to serve as a global reference center, contributing to better understanding, control, and disease prevention. Such advancement aims to boost the adoption of the products and market growth in the region.

Latin America & Middle East & Africa

Latin America and the Middle East & Africa held comparatively lower shares but are expected to grow during the forecast period. The growth of the market is augmented by the increasing prevalence of vaccine-preventable infectious diseases and rising initiatives to eliminate the disease through immunization drives propel the market’s growth in the region.

• For instance, in April 2025, the Governments of the Cooperative Republic of Guyana and Brazil, in collaboration with the Pan American Health Organization/World Health Organization (PAHO/WHO), launched Cross-Border Vaccination Week, intending to enhance immunization coverage and strengthen disease prevention efforts among vulnerable populations. Such activities are expected to boost the adoption of vaccines and lead the market growth.

COMPETITIVE LANDSCAPE

KEY INDUSTRY PLAYERS

Strategic Initiatives of GSK plc, Merck & Co., Inc., and Sanofi to Enable Them to Maintain Their Market Positions

This market holds a consolidated structure with players such as GSK plc, Sanofi, Merck & Co., Inc., accounting for a substantial share in 2024. Top companies of diphtheria, tetanus, and pertussis (DTP) vaccines hold their position by providing robust product offerings, strategic initiatives such as collaboration, and consistent research and development strategies to offer exclusive products.

Other key players with an important presence in the global and regional market are Serum Institute of India Pvt. Ltd., Wuhan Institute of Biological Products Co., Ltd., Boryung Biopharma Co., Ltd., and BioNet-Asia, with key products and strategic initiatives to offer cost-effective products, are expected to maintain their position in the market.

LIST OF KEY DIPHTHERIA, TETANUS, AND PERTUSSIS (DTP) VACCINE COMPANIES PROFILED

• GSK plc (U.K.)
• Sanofi (France)
• Merck & Co., Inc. (U.S.)
• Boryung Biopharma Co. (South Korea)
• Serum Institute of India Pvt. Ltd. (India)
• Wuhan Institute of Biological Products Co., Ltd. (China)
• BioNet-Asia.(Thailand)
• Bio Farma (Indonesia)
• Biological E Limited. (India)

KEY INDUSTRY DEVELOPMENTS

• June 2025- BioNet-Asia participated in the Asia Pacific Summit on Medical and Clinical Vaccinology (APS-MCV), intending to discuss the company’s latest innovations in pertussis prevention and explore the advantages of recombinant pertussis vaccines to address the resurgence of disease across the region.
• May 2025- BioNet-Asia collaborated with PT Bio Farma and signed a Memorandum of Understanding (MoU), intending to develop and distribute a combined TdaP vaccine (tetanus, diphtheria, and acellular recombinant pertussis).
• October 2024- GSK plc invested around USD 800.0 million to develop state-of-the-art drug substance manufacturing in the U.S. The facility was accompanied by multi-purpose facilities capable of manufacturing sterile liquid vaccines and medicines.
• June 2024- Merck & Co., Inc. announced that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) voted to add VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine) to its preferred recommendation for the vaccination.
• September 2020- Sanofi launched Tetraxim (DTaP-IPV) in India. The booster vaccine is indicated
• for preschoolers and protects against four major diseases - Diphtheria, Pertussis, Tetanus, and Polio.

REPORT COVERAGE

The global diphtheria, tetanus, and pertussis (DTP) vaccines market report provides detailed industry analysis. It focuses on key market aspects, such as the epidemiology of key diseases overview of diphtheria, tetanus, and pertussis (DTP) vaccines types. Additionally, it includes an overview of reimbursement scenarios by different countries, pipeline analysis, and vaccination coverage by key countries. Furthermore, insights on new product launches and key industry developments, such as mergers, partnerships, & acquisitions, are mentioned in the report. Besides these, it offers insights into the market trends in diphtheria, tetanus, and pertussis (DTP) vaccine development.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation